



# Review decision – May 2021

Review decision

Published: 28 May 2021

[www.nice.org.uk](http://www.nice.org.uk)

## Decision that an update is not needed

We would like to update you on the decision made regarding the review of the existing NICE technology appraisal guidance on sorafenib for treating advanced hepatocellular carcinoma.

NICE has been considering whether sufficient new evidence has emerged for the appraisal committee to be asked to undertake a full update of the guidance.

The original guidance was an optimised recommendation, no new evidence suggests that the recommendation should be broadened to other subgroups.

NICE has decided that the guidance remains relevant and an update is not needed. It will remain in place, in its current form, unless NICE becomes aware of substantive information which would make it reconsider.

[Review decision paper](#)